Gabriël E. Jacobs

The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Kasper Recourt, Peter de Boer, Rob Zuiker et al. · Translational Psychiatry · 2019 · 83 citations · Full text

Medicine, Pharmacology, Psychiatry +17

The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

Sander Brooks, Gabriël E. Jacobs, Peter de Boer et al. · Journal of Psychopharmacology · 2019 · 73 citations

Medicine, Pharmacology, Psychiatry +17

Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Kasper Recourt, Peter de Boer, Peter van der Ark et al. · Translational Psychiatry · 2023 · 60 citations · Full text

Medicine, Pharmacology, Psychiatry +17

Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial

Kasper Recourt, Jasper van der Aart, Gabriël E. Jacobs et al. · Journal of Psychopharmacology · 2020 · 58 citations

Medicine, Neuroscience, Pharmacology +14

Does olanzapine inhibit the psychomimetic effects of Δ ⁹ -tetrahydrocannabinol?

Daniël Kleinloog, M Liem-Moolenaar, Gabriël E. Jacobs et al. · Journal of Psychopharmacology · 2012 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17